Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs and Monotherapy Who Have an Inadequate Response to Current Non-Biologic or Biologic DMARDs
Status: Archived
Clinical Trial Facility
2423
mi
from 98109
Charleston, SC
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs and Monotherapy Who Have an Inadequate Response to Current Non-Biologic or Biologic DMARDs
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2423
mi
from 98109
Charleston, SC
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs and Monotherapy Who Have an Inadequate Response to Current Non-Biologic or Biologic DMARDs
Status: Archived
Clinical Trial Facility
1263
mi
from 98109
Sioux Falls, SD
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs and Monotherapy Who Have an Inadequate Response to Current Non-Biologic or Biologic DMARDs
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1263
mi
from 98109
Sioux Falls, SD
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs and Monotherapy Who Have an Inadequate Response to Current Non-Biologic or Biologic DMARDs
Status: Archived
Clinical Trial Facility
1971
mi
from 98109
Nashville, TN
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs and Monotherapy Who Have an Inadequate Response to Current Non-Biologic or Biologic DMARDs
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1971
mi
from 98109
Nashville, TN
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs and Monotherapy Who Have an Inadequate Response to Current Non-Biologic or Biologic DMARDs
Status: Archived
Clinical Trial Facility
1770
mi
from 98109
Austin, TX
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs and Monotherapy Who Have an Inadequate Response to Current Non-Biologic or Biologic DMARDs
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1770
mi
from 98109
Austin, TX
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs and Monotherapy Who Have an Inadequate Response to Current Non-Biologic or Biologic DMARDs
Status: Archived
Clinical Trial Facility
2325
mi
from 98109
Burlington, VT
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs and Monotherapy Who Have an Inadequate Response to Current Non-Biologic or Biologic DMARDs
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2325
mi
from 98109
Burlington, VT
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs and Monotherapy Who Have an Inadequate Response to Current Non-Biologic or Biologic DMARDs
Status: Archived
Clinical Trial Facility
2351
mi
from 98109
Richmond, VA
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs and Monotherapy Who Have an Inadequate Response to Current Non-Biologic or Biologic DMARDs
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2351
mi
from 98109
Richmond, VA
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs and Monotherapy Who Have an Inadequate Response to Current Non-Biologic or Biologic DMARDs
Status: Archived
Clinical Trial Facility
10
mi
from 98109
Mountlake Terrace, WA
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs and Monotherapy Who Have an Inadequate Response to Current Non-Biologic or Biologic DMARDs
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
10
mi
from 98109
Mountlake Terrace, WA
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs and Monotherapy Who Have an Inadequate Response to Current Non-Biologic or Biologic DMARDs
Status: Archived
Clinical Trial Facility
2161
mi
from 98109
Morgantown, WV
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs and Monotherapy Who Have an Inadequate Response to Current Non-Biologic or Biologic DMARDs
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2161
mi
from 98109
Morgantown, WV
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs and Monotherapy Who Have an Inadequate Response to Current Non-Biologic or Biologic DMARDs
Status: Archived
Clinical Trial Facility
1687
mi
from 98109
Milwaukee, WI
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs and Monotherapy Who Have an Inadequate Response to Current Non-Biologic or Biologic DMARDs
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1687
mi
from 98109
Milwaukee, WI
Low Level Magnetic Fields for the Treatment of Osteoarthritis of the Hip
A Randomized, Double-blind, Placebo-controlled Evaluation of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Osteoarthritis of the Hip: Pilot Study Protocol
Status: Archived
Innovative Research
2512
mi
from 98109
Clearwater, FL
Low Level Magnetic Fields for the Treatment of Osteoarthritis of the Hip
A Randomized, Double-blind, Placebo-controlled Evaluation of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Osteoarthritis of the Hip: Pilot Study Protocol
Status: Archived
Updated: 1/1/1970
Innovative Research
2512
mi
from 98109
Clearwater, FL
Low Intensity Resistance Training With Partial Blood Flow Restriction for Quadriceps Strengthening
Determining Efficacy of a Tolerable Means of Strengthening for Older Adults With Knee Osteoarthritis: Partial Blood Flow Restriction Low Intensity Resistance Training
Status: Archived
University of Iowa
1556
mi
from 98109
Iowa City, IA
Low Intensity Resistance Training With Partial Blood Flow Restriction for Quadriceps Strengthening
Determining Efficacy of a Tolerable Means of Strengthening for Older Adults With Knee Osteoarthritis: Partial Blood Flow Restriction Low Intensity Resistance Training
Status: Archived
Updated: 1/1/1970
University of Iowa
1556
mi
from 98109
Iowa City, IA
Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects
An Open-Label, Single Center Study to Assess the Pharmacokinetics of Pioglitazone in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily
Status: Archived
Clinical Research Facility
1500
mi
from 98109
Kansas City, KA
Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects
An Open-Label, Single Center Study to Assess the Pharmacokinetics of Pioglitazone in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1500
mi
from 98109
Kansas City, KA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
2079
mi
from 98109
Birmingham, AL
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2079
mi
from 98109
Birmingham, AL
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
1104
mi
from 98109
Peoria, AZ
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1104
mi
from 98109
Peoria, AZ
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
1782
mi
from 98109
Little Rock, AR
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1782
mi
from 98109
Little Rock, AR
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
711
mi
from 98109
Santa Clara, CA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
711
mi
from 98109
Santa Clara, CA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
2550
mi
from 98109
Celebration, FL
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2550
mi
from 98109
Celebration, FL
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
2178
mi
from 98109
Atlanta, GA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2178
mi
from 98109
Atlanta, GA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
2679
mi
from 98109
Honolulu, HI
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2679
mi
from 98109
Honolulu, HI
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
259
mi
from 98109
Coeur D'Alene, ID
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
259
mi
from 98109
Coeur D'Alene, ID
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
1939
mi
from 98109
Jeffersonville, IN
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1939
mi
from 98109
Jeffersonville, IN
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
1938
mi
from 98109
Louisville, KY
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1938
mi
from 98109
Louisville, KY
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
2317
mi
from 98109
Chevy Chase, MD
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2317
mi
from 98109
Chevy Chase, MD
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
2485
mi
from 98109
Boston, MA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2485
mi
from 98109
Boston, MA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
1933
mi
from 98109
Detroit, MI
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1933
mi
from 98109
Detroit, MI
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
1984
mi
from 98109
Jackson, MS
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1984
mi
from 98109
Jackson, MS
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
1366
mi
from 98109
Omaha, NE
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1366
mi
from 98109
Omaha, NE
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
1184
mi
from 98109
Albuquerque, NM
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1184
mi
from 98109
Albuquerque, NM
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
2281
mi
from 98109
Charlotte, NC
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2281
mi
from 98109
Charlotte, NC
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
1931
mi
from 98109
Lima, OH
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1931
mi
from 98109
Lima, OH
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
2373
mi
from 98109
Philadelphia, PA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2373
mi
from 98109
Philadelphia, PA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
2423
mi
from 98109
Charleston, SC
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2423
mi
from 98109
Charleston, SC
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
1263
mi
from 98109
Sioux Falls, SD
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1263
mi
from 98109
Sioux Falls, SD
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
1971
mi
from 98109
Nashville, TN
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1971
mi
from 98109
Nashville, TN
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
1770
mi
from 98109
Austin, TX
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1770
mi
from 98109
Austin, TX
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
675
mi
from 98109
Ogden, UT
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
675
mi
from 98109
Ogden, UT
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
2351
mi
from 98109
Richmond, VA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2351
mi
from 98109
Richmond, VA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
10
mi
from 98109
Mountlake Terrace, WA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
10
mi
from 98109
Mountlake Terrace, WA
Study of Adalimumab in Subjects With Axial Spondyloarthritis
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis
Status: Archived
Clinical Research Facility
2080
mi
from 98109
Birmingham, AL
Study of Adalimumab in Subjects With Axial Spondyloarthritis
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2080
mi
from 98109
Birmingham, AL
Study of Adalimumab in Subjects With Axial Spondyloarthritis
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis
Status: Archived
Clinical Research Facility
1070
mi
from 98109
Colorado Springs, CO
Study of Adalimumab in Subjects With Axial Spondyloarthritis
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1070
mi
from 98109
Colorado Springs, CO
Study of Adalimumab in Subjects With Axial Spondyloarthritis
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis
Status: Archived
Clinical Research Facility
1025
mi
from 98109
Denver, CO
Study of Adalimumab in Subjects With Axial Spondyloarthritis
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1025
mi
from 98109
Denver, CO
Study of Adalimumab in Subjects With Axial Spondyloarthritis
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis
Status: Archived
Clinical Research Facility
2329
mi
from 98109
Baltimore, MD
Study of Adalimumab in Subjects With Axial Spondyloarthritis
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2329
mi
from 98109
Baltimore, MD
Study of Adalimumab in Subjects With Axial Spondyloarthritis
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis
Status: Archived
Clinical Research Facility
2316
mi
from 98109
Wheaton, MD
Study of Adalimumab in Subjects With Axial Spondyloarthritis
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2316
mi
from 98109
Wheaton, MD
Study of Adalimumab in Subjects With Axial Spondyloarthritis
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis
Status: Archived
Clinical Research Facility
149
mi
from 98109
Portland, OR
Study of Adalimumab in Subjects With Axial Spondyloarthritis
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
149
mi
from 98109
Portland, OR
Study of Adalimumab in Subjects With Axial Spondyloarthritis
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis
Status: Archived
Altoona Center for Clinical Research
2206
mi
from 98109
, PA
Study of Adalimumab in Subjects With Axial Spondyloarthritis
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis
Status: Archived
Updated: 1/1/1970
Altoona Center for Clinical Research
2206
mi
from 98109
, PA
Study of Adalimumab in Subjects With Axial Spondyloarthritis
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis
Status: Archived
Clinical Research Facility
2323
mi
from 98109
Wyomissing, PA
Study of Adalimumab in Subjects With Axial Spondyloarthritis
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2323
mi
from 98109
Wyomissing, PA
Study of Adalimumab in Subjects With Axial Spondyloarthritis
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis
Status: Archived
Clinical Research Facility
1678
mi
from 98109
Dallas, TX
Study of Adalimumab in Subjects With Axial Spondyloarthritis
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1678
mi
from 98109
Dallas, TX
Study of Adalimumab in Subjects With Axial Spondyloarthritis
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis
Status: Archived
Clinical Research Facility
1892
mi
from 98109
Houston, TX
Study of Adalimumab in Subjects With Axial Spondyloarthritis
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1892
mi
from 98109
Houston, TX
Study of Adalimumab in Subjects With Axial Spondyloarthritis
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis
Status: Archived
Clinical Research Facility
2
mi
from 98109
Seattle, WA
Study of Adalimumab in Subjects With Axial Spondyloarthritis
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2
mi
from 98109
Seattle, WA
AMG 827 in Rheumatoid Arthritis Subjects With Inadequate Response to Methotrexate
A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Status: Archived
Clinical Research Facility
2079
mi
from 98109
Birmingham, AL
AMG 827 in Rheumatoid Arthritis Subjects With Inadequate Response to Methotrexate
A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2079
mi
from 98109
Birmingham, AL